Literature DB >> 20635768

Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry.

S S Iyengar1, Tiny Nair, I Sathyamurthy, J S Hiremath, U Jadhav, D Kumbla, R K Jain, M Srinivasan, P K Sahoo, Kamaldeep Chawla, V K Katiyal.   

Abstract

OBJECTIVE: to study the efficacy and safety of indigenously developed tenecteplase injection in the management of Indian STEMI patients in clinical practice.
METHODS: post-licensure, observational, prescription event monitoring study.
RESULTS: 2100 patients received weight-adjusted tenecteplase injection. More than 90% patients received aspirin, clopidogrel, and enoxaparin/heparin. Clinically successful thrombolysis was reported in 86.71%, in-hospital mortality was 3.48%. The adverse events recorded were comparable with previously published data. Any bleeding (excluding intra-cranial hemorrhage) was seen in 4.62% patients which was reported in 0.90% patients of which 47.34% patients had also received GpIIb/IIIa inhibitors.
CONCLUSION: This study confirms the efficacy and safety of indigenous tenecteplase in Indian STEMI patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20635768

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  2 in total

1.  Two-year follow-up data from the STEPP-AMI study: A prospective, observational, multicenter study comparing tenecteplase-facilitated PCI versus primary PCI in Indian patients with STEMI.

Authors:  Suma M Victor; S Vijayakumar; Thomas Alexander; C G Bahuleyan; Arun Srinivas; S Selvamani; S Marutha Priya; K Kamaleswari; Ajit S Mullasari
Journal:  Indian Heart J       Date:  2016-01-12

2.  A prospective, observational, multicentre study comparing tenecteplase facilitated PCI versus primary PCI in Indian patients with STEMI (STEPP-AMI).

Authors:  Suma M Victor; Vijayakumar Subban; Thomas Alexander; Bahuleyan C G; Arun Srinivas; Selvamani S; Ajit S Mullasari
Journal:  Open Heart       Date:  2014-08-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.